Chapter 2 Summary and Highlights
Chapter 3 Market Overview
- Introduction
- History of Nucleic Acid Drugs
- Antisense Oligonucleotides
- Rna
- Drug Delivery System
- Nucleic Acid Drugs
- Inhibition Type
- Antisense Oligonucleotide
- Regulations
- Pre-Clinical Inda
- Covid-19 Impact Analysis on the Rnai Drug Delivery Markets
- Positive Impact of Covid-19
- Negative Effect of Covid-19
Chapter 4 Market Dynamics
- Market Drivers
- Approved Rnai Drugs
- Venture Funding Increased in Rnai Drugs
- Rnai Drugs Designated as Orphan Drugs
- New Nanoparticle Technologies for Drug Delivery Systems
- Market Restraints
- High Drug Costs
- Lack of Awareness Regarding Rare Diseases
- Clustered Regularly Interspaced Short Palindromic Repeats Technology Application Growing
- Market Opportunities
- Application in Cancer Treatment
- Infectious Disease and Rnai Drugs
Chapter 5 Nucleic Acid Drug Delivery Technology Market by Type
- Encapsulation
- Viral Vector-Based
- Non-Viral Vector-Based Delivery System
- Conjugates
Chapter 6 Market Breakdown by Application
- Drug Development and Discovery
- Process of Rna-Based Drug Discovery
- Design of Rnai Drugs
- Sequence Optimization
- Chemical Modification
- Targeted Delivery
- Therapeutic Application
Chapter 8 Market Breakdown by Molecules
- Small Interfering Ribonucleic Acid
- Antisense Oligonucleotide
- Fomivirsen (Vitravene)
- Mipomersen
- Nusinersen (Spinraza)
- Inotersen (Tegsedi)
- Eteplirsen (Exondys 51)
- Golodirsen (Vyondys 53)
- Milasen: a Unique Personalized Medicine
- Messenger Rna
- Others
- Aptamers
- Micro Rna
Chapter 9 Market Breakdown by Therapeutic Area
- Oncology
- Rare and Genetic Diseases
- Central Nervous System
- Respiratory
- Other Disease
Chapter 10 Market Breakdown by Region
- North America
- Europe
- Asia-Pacific
- Japan
- South Korea
- China
- India
- Australia
- Rest of the World
Chapter 11 Environmental, Social and Governance in the Biotechnology Sector
- Key Environmental, Social and Governance Issues in the Biotechnology Industry
- Biotechnology Industry Environmental, Social and Governance Performance Analysis
- Environmental Performance
- Social Performance
- Governance Performance
- Consumer Perspective on Esg in Biotechnology
- Case Study
- Concluding Remarks
Chapter 12 Emerging Technologies and Developments
- Drug Delivery to Lungs
- Nanotechnology
- Use of Artificial Intelligence and Machine Learning
Chapter 13 Clinical Trial and Patent Analysis
- Clinical Trials Analysis
- Patent Analysis
Chapter 14 Mergers and Acquisitions and Funding Outlook
- Start-Up Funding in Nucleic Acid Delivery Technology
Chapter 16 Company Profiles
- Alnylam Pharmaceuticals Inc.
- Arcturus Therapeutics Inc.
- Arbutus Biopharma Corp.
- Arrowhead Pharmaceuticals Inc.
- Benitec Biopharma
- Cellecta Inc.
- Eleven Therapeutics
- Genevant Sciences Corp.
- Ionis Pharmaceuticals Inc.
- Mirimus, Inc.
- Novo Nordisk
- Nanode Therapeutics Inc.
- Olix Pharmaceuticals
- Phio Pharmaceuticals Corp.
- Silence Therapeutics plc
- Sirnaomics Inc.
- Somagenics, Inc.
List of Tables
Summary Table: Global Market for Nucleic Acid Drug Delivery, by Type, Through 2028
Table 1: Challenges for the Delivery of Nucleic Acid Drugs
Table 2: Differences Between Small Molecule Drugs and Biological Drugs
Table 3: Nucleic Acid Drug Classification
Table 4: Nucleic Acid Drug Types
Table 5: siRNA Therapeutics for SARS-CoV-2, SARS-CoV-1 and MERS-CoV, 2021
Table 6: Orphan Drug Incentives in Various Countries
Table 7: Direct Methods of Insertion into the Cell
Table 8: Advantages and Disadvantages of Various Kinds of Drug Delivery Systems
Table 9: Advantages and Disadvantages of Viral Vectors
Table 10: Global Market for Nucleic Acid Drug Delivery, by Encapsulation Material Type, Through 2028
Table 11: Lipid Nanoparticles and Their Functions
Table 12: Lipid Nanoparticle Types and Their Advantages and Disadvantages
Table 13: Comparison of Polymeric Vectors and Lipid-Based Vectors
Table 14: Polymer Types for Nucleic Acid Drug Delivery and Their Properties
Table 15: Global Market for Nucleic Acid Drug Delivery, by Application, Through 2028
Table 16: Approved Nucleic Acid Drugs, upto June 2023
Table 17: Routes of Administration for Nucleic Acid Drugs
Table 18: Global Market for Nucleic Acid Drug Delivery, by Route of Aministration, Through 2028
Table 19: Characteristics of Different Molecule Types for Nucleic Acid Drug
Table 20: Global Market for Nucleic Acid Drug Delivery, by Molecule Type, Through 2028
Table 21: Comparison ASO Versus siRNA
Table 22: Various mRNA Drugs Under Clinical Trials, June 2023
Table 23: Comaprision of miRNA and siRNA
Table 24: Global Market for Nucleic Acid Drug Delivery, by Therapeutic Area, Through 2028
Table 25: Global Market for Nucleic Acid Drug Delivery, by Region, Through 2028
Table 26: North American Market for Nucleic Acid Drug Delivery, by Type, Through 2028
Table 27: North American Market for Non-Viral Vector Nucleic Acid Drug Delivery, by Type, Through 2028
Table 28: U.S. Biotech Private Rounds for Nucleic Acid-Based, June 2022
Table 29: European Market for Nucleic Acid Drug Delivery, by Type, Through 2028
Table 30: European Market for Non-Viral Vector Nucleic Acid Drug Delivery, by Type, Through 2028
Table 31: Asia-Pacific Market for Nucleic Acid Drug Delivery, by Type, Through 2028
Table 32: Asia-Pacific Market for Non-Viral Vector Nucleic Acid Drug Delivery, by Type, Through 2028
Table 33: Rest of the World Market for Nucleic Acid Drug Delivery, by Type, Through 2028
Table 34: Rest of the World Market for Non-Viral Vector Nucleic Acid Drug Delivery, by Type, Through 2028
Table 35: Alnylam ESG initiatives
Table 36: Patents Issued on Nucleic Acid Drug Deivery, 2000-2020
Table 37: Collaboration in Nucleic Acid Drug Delivery Market, 2021-2023
Table 38: Start-Up Funding in the Nucleic Acid Drug Delivery Industry, January 2022 and March 2023
Table 39: Collaborations in the Nucleic Acid Drug Delivery Market, 2021-2023
Table 40: Clinical Trials and Approvals in the Nucliec Acid Drug Delivery Market, 2021-2023
Table 41: Other Strategic Developments in Nucleic Acid Drug Delivery Market, 2021-2023
Table 42: Alnylam Pharmaceuticals Inc.: Annual Revenue, 2022
Table 43: Alnylam Pharmaceuticals: Pipeline Products
Table 44: Alnylam Pharmaceuticals: Product Portfolio
Table 45: Alnylam Pharmaceuticals: Recent Developments, 2021-2023
Table 46: Arcturus Therapeutics Inc.: Annual Revenue, 2022
Table 47: Arcturus Therapeutics: Pipeline Products
Table 48: Arcturus Therapeutics: Recent Developments, 2021-2023
Table 49: Arbutus Biopharma Corp.: Collaborations, 2021-2023
Table 50: Arbutus Biopharma Corp.: Annual Revenue, 2022
Table 51: Arbutus Biopharma Corp.: Recent Developments, 2021-2023
Table 52: Pipeline of Arrowhead Pharmaceuticals
Table 53: Benitec Biopharma: Annual Revenue, 2022
Table 54: Eleven Therapeutics: Recent Developments, 2022
Table 55: Genevant: Recent Developments, 2021 and 2022
Table 56: Ionis Phamaceutical Inc.: Annual Revenue, 2022
Table 57: Pipeline Products of Ionis Pharmaceuticals
Table 58: Ionis Pharmaceuticals Inc.: Recent Developments, 2023
Table 59: Mirimus Inc.: Recent Developments, 2021 and 2022
Table 60: Novo Nordisk: Annual Revenue, 2022
Table 61: Pipeline Products of Novo Nordisk
Table 62: Pipeline Products of Nanode Therapeutics
Table 63: Olix Pharmaceuticals: Recent Developments, 2021-2023
Table 64: Slience Therapeutics: Annual Revenue, 2022
Table 65: Pipeline of Silence Therapeutics
Table 66: Silence Therapeutics: Recent Developments, 2023
Table 67: Pipeline of Sirnaomics Inc.
Table 68: Sirnaomics Inc.: Recent Developments, 2021-2023
List of Figures
Summary Figure: Global Market for Nucleic Acid Drug Delivery, by Type, 2020-2028
Figure 1: Timeline of Nucleic Acid Therapeutics, Since 1950s
Figure 2: Enzymes Needed for RNA-Based Drugs
Figure 3: Basic Function of a Drug Delivery System
Figure 4: Challenges Faced by RNA-Based Drug Delivery
Figure 5: Nucleic Acid Drug Types
Figure 6: Clinical Trial Flow
Figure 7: Clinical Trial Specifications
Figure 8: Share of Various Viruses Under Study for Vaccine Development
Figure 9: Research on Virologoly During the COVID-19 Pandemic
Figure 10: RNA-Based Drugs Under Development, 2017-2022
Figure 11: Total RNA-Based Funding, by Venture Capitalists, 2017-2021
Figure 12: Corporate-Backed RNA Financing, 2017-2021
Figure 13: Financial Benefits for Orphan Drugs
Figure 14: Nano-Delivery Types Used for Nucleic Acid Drug Delivery
Figure 15: Global Market Shares of Nucleic Acid Drug Delivery Sytems, by Type, 2022
Figure 16: Drug Delivery of Nucleic Acid Drugs, by Types
Figure 17: Viral Vector Types
Figure 18: Global Market for Conjugate Drug Delivery Systems of Nucleic Acids, 2020-2028
Figure 19: Gene Therapy Types
Figure 20: RNA-Based Drugs in Research and Development, 2022
Figure 21: Initial Issues with RNA-Based Drugs
Figure 22: RNA Drug Designing
Figure 23: Market Breakdown by Route of Administration Types and Subtypes
Figure 24: siRNA Delivery System
Figure 25: Antisense Oligonucleotide Mechanism of Action
Figure 26: Global Market Shares of Nulceic Acid Drug Delivery Systems, by Therapeutic Area, 2022
Figure 27: Global Market for Nucleic Acid Drug Delivery, by Region, 2020-2028
Figure 28: Share of Biotechnology Firms Reporting and Not Reporting ESG Data, 2022
Figure 29: ESG Disclosure in Various Company Specific Documents in Biotechnology Industry, 2022
Figure 30: Share of ESG Disclosure During the Forecasted Period in the Biotechnology Industry
Figure 31: Share of ESG Significnace in the Biotechnology Industry
Figure 32: Major Environmental Concerns in the Biotechnology Industry, 2023
Figure 33: Major Social Concerns in the Biotechnology Industry
Figure 34: Major Governance Concerns in the Biotechnology Industry
Figure 35: Share of Clinical Trials of RNA Therapeutics, by Clinical Trial Phase, 2020-2022
Figure 36: Share of Clinical Trials of RNA Therapeutics, by Age Group, 2022
Figure 37: Share of Clinical Trials of RNA Therapeutics, by Gender, 2022
Figure 38: Share of Clinical Trials of RNA Therapeutics, by Investors, 2022
Figure 39: Share of Clinical Trials of RNA Therapeutics, by Recruitment Status, 2022
Figure 40: Share of Clinical Trials of RNA Therapeutics Based on Study Results
Figure 41: Start-Up Funding in the Nucleic Acid Drug Delivery Industry, by Various Rounds, 2022 and 2023
Figure 42: Distribution Share of Start-Up Funding in the Nucleic Acid Drug Delivery Industry, by Various Rounds, 2022 and 2023
Figure 43: Global Market Shares of Nucleic Acid Drug Deivery, by Various Growth Strategies, 2022
Figure 44: Alnylam Pharmaceuticals: Annual Revenue, 2021 and 2022
Figure 45: Alnylam Pharmaceuticals: Revenue Share, by Products, 2022
Figure 46: Alnylam Pharmaceuticals: Revenue Share, by Region, 2022
Figure 47: Arcturus Therapeutics: Annual Revenue, 2021 and 2022
Figure 48: Arbutus Biopharma Corp.: Annual Revenue, 2021 and 2022
Figure 49: Arbutus Biopharma Corp.: Revenue Share, by Type, 2022
Figure 50: Benitec Biopharma: Annual Revenue, 2021 and 2022
Figure 51: Ionis Phamaceutical: Annual Revenue, 2021 and 2022
Figure 52: Novo Nordisk: Annual Revenue, 2021 and 2022
Figure 53: Novo Nordisk: Revenue Share, by Segments, 2022
Figure 54: Novo Nordisk: Revenue Share, by Region, 2022
